Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 184

1.

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2 Study.

Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C; Peficitinib-UC Study Group.

J Crohns Colitis. 2018 Jun 15. doi: 10.1093/ecco-jcc/jjy085. [Epub ahead of print]

PMID:
29917064
2.

Correction: ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Lichtenstein GR, Loftus EV Jr, Isaacs KL, Regueiro MD, Gerson LB, Sands BE.

Am J Gastroenterol. 2018 Jun 12. doi: 10.1038/s41395-018-0120-x. [Epub ahead of print]

PMID:
29895986
3.

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients with Crohn's Disease.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV Jr, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C.

Gastroenterology. 2018 May 29. pii: S0016-5085(18)34572-4. doi: 10.1053/j.gastro.2018.05.039. [Epub ahead of print]

PMID:
29857091
4.

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG.

Aliment Pharmacol Ther. 2018 Jul;48(1):65-77. doi: 10.1111/apt.14794. Epub 2018 May 24.

PMID:
29797519
5.

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Casteele NV, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS.

Inflamm Bowel Dis. 2018 May 18. doi: 10.1093/ibd/izy171. [Epub ahead of print]

PMID:
29788240
6.

The Effects of Ustekinumab on Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease.

Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, Lang Y, Targan S, Sandborn WJ, Feagan BG.

J Crohns Colitis. 2018 May 3. doi: 10.1093/ecco-jcc/jjy055. [Epub ahead of print]

PMID:
29726939
7.

ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE.

Am J Gastroenterol. 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27. Erratum in: Am J Gastroenterol. 2018 Jun 12;:.

PMID:
29610508
8.

Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease.

Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L.

Gastroenterology. 2018 Mar 28. pii: S0016-5085(18)30339-1. doi: 10.1053/j.gastro.2018.03.032. [Epub ahead of print]

PMID:
29601825
9.

Luminally-polarized mural and vascular remodeling in ileal strictures of Crohn's Disease.

Zhang X, Ko HM, Torres J, Panchal HJ, Cai Z, Wagner M, Sands BE, Colombel JF, Cho J, Taouli B, Harpaz N.

Hum Pathol. 2018 Mar 16. pii: S0046-8177(18)30081-9. doi: 10.1016/j.humpath.2018.03.004. [Epub ahead of print]

PMID:
29555578
10.

Opportunistic screening for bone disease using abdominal CT scans obtained for other reasons in newly diagnosed IBD patients.

Rebello D, Anjelly D, Grand DJ, Machan JT, Beland MD, Furman MS, Shapiro J, LeLeiko N, Sands BE, Mallette M, Bright R, Moniz H, Merrick M, Shah SA.

Osteoporos Int. 2018 Mar 8. doi: 10.1007/s00198-018-4444-6. [Epub ahead of print]

PMID:
29520605
11.

Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis.

Shah SC, Naymagon S, Panchal HJ, Sands BE, Cohen BL, Dubinsky MC.

Inflamm Bowel Dis. 2018 Feb 15;24(3):651-659. doi: 10.1093/ibd/izx039.

PMID:
29462380
12.

What Is the Role of the Inflammatory Bowel Disease Panel in Diagnosis and Treatment?

Long MD, Sands BE.

Clin Gastroenterol Hepatol. 2018 May;16(5):618-620. doi: 10.1016/j.cgh.2018.02.010. Epub 2018 Feb 15. No abstract available.

PMID:
29454043
13.

When Do You Start and When Do You Stop Screening for Colon Cancer in Inflammatory Bowel Disease?

Long MD, Sands BE.

Clin Gastroenterol Hepatol. 2018 May;16(5):621-623. doi: 10.1016/j.cgh.2018.02.011. Epub 2018 Feb 14. No abstract available.

PMID:
29454042
14.

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I.

J Crohns Colitis. 2018 Mar 28;12(4):510. doi: 10.1093/ecco-jcc/jjx168. No abstract available.

PMID:
29385425
15.

Clinical experience and two-year follow-up with a one-piece viscoelastic cervical total disc replacement.

Chin KR, Lubinski JR, Zimmers KB, Sands BE, Pencle F.

J Spine Surg. 2017 Dec;3(4):630-640. doi: 10.21037/jss.2017.12.03.

16.

Practices, attitudes, and knowledge about Crohn's disease and smoking cessation among gastroenterologists.

Nulsen B, Sands BE, Shah BJ, Ungaro RC.

Eur J Gastroenterol Hepatol. 2018 Feb;30(2):155-160. doi: 10.1097/MEG.0000000000001010.

PMID:
29240002
17.

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus.

Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, Derieppe M, Dignass A, Driscoll R, Fitzpatrick R, Gaarentstroom-Lunt J, Higgins PD, Kotze PG, Meissner J, O'Connor M, Ran ZH, Siegel CA, Terry H, van Deen WK, van der Woude CJ, Weaver A, Yang SK, Sands BE, Vermeire S, Travis SP.

J Crohns Colitis. 2018 Mar 28;12(4):408-418. doi: 10.1093/ecco-jcc/jjx161.

PMID:
29216349
18.

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.

J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133.

19.

Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.

Feagan BG, Sands BE, Rossiter G, Li X, Usiskin K, Zhan X, Colombel JF.

Gastroenterology. 2018 Jan;154(1):61-64.e6. doi: 10.1053/j.gastro.2017.08.035. Epub 2017 Aug 25.

20.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.

N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.

Supplemental Content

Loading ...
Support Center